Genmab A/S (CPH: GMAB)

Market Cap	98.54B
Revenue (ttm)	19.84B
Net Income (ttm)	4.70B
Shares Out	63.51M
EPS (ttm)	72.21
PE Ratio	21.49
Forward PE	19.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,643
Open	1,560.00
Previous Close	1,551.50
Day's Range	1,539.50 - 1,567.00
52-Week Range	1,431.00 - 2,283.00
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Genmab

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 2,204
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: GMAB

Financial Performance

In 2023, Genmab's revenue was 16.47 billion, an increase of 13.57% compared to the previous year's 14.51 billion. Earnings were 4.35 billion, a decrease of -20.18%.